Antibody targeting CLDN18.2, and preparation method and application of antibody
The invention discloses an antibody targeting CLDN18.2, and a preparation method and application of the antibody. The antibody comprises VL and/or VH, wherein the VH comprises the following CDR sequences: a VH CDR1 amino acid sequence as shown in SEQ ID NO: 6, a VH CDR2 amino acid sequence as shown...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Patent |
| Sprache: | chi ; eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | ZHENG MINGJIN WANG JIELI ZHANG WEI |
| description | The invention discloses an antibody targeting CLDN18.2, and a preparation method and application of the antibody. The antibody comprises VL and/or VH, wherein the VH comprises the following CDR sequences: a VH CDR1 amino acid sequence as shown in SEQ ID NO: 6, a VH CDR2 amino acid sequence as shown in SEQ ID NO: 7, and/or a VH CDR3 amino acid sequence as shown in SEQ ID NO: 8; and the VL comprises the following CDR sequences: a VL CDR1 amino acid sequence as shown in SEQ ID NO: 17, a VL CDR2 amino acid sequence as shown in SEQ ID NO: 18, and/or a VL CDR3 amino acid sequence as shown in SEQ ID NO: 19. Compared with the prior art, the antibody provided by the invention has obvious advantages of high binding affinity, good ADCC, CDC and growth inhibition effects, high endocytosis activity and the like.
本发明公开了靶向CLDN18.2的抗体及其制备方法和应用。所述抗体包含VL和/或VH，所述VH包含以下CDR序列：如SEQ ID NO:6所示的VH CDR1氨基酸序列；如SEQ ID NO:7所示的VH CDR2氨基酸序列；和/或如SEQ ID NO:8所示的VH CDR3氨基酸序列；所述VL包含以下的CDR序列：如SEQ ID NO:17所示的VL CDR1氨基酸序列；如SEQ ID NO:18所示的VL CDR2氨基 |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CN112707965A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CN112707965A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CN112707965A3</originalsourceid><addsrcrecordid>eNrjZPB3zCvJTMpPqVQoSSxKTy3JzEtXcPZx8TO00DPSUUjMS1EoKEotSCxKLMnMz1PITS3JyE8BCycWFORkJkOE89OAQhBjeBhY0xJzilN5oTQ3g6Kba4izh25qQX58anFBYnJqXmpJvLOfoaGRuYG5pZmpozExagCpqjXG</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Antibody targeting CLDN18.2, and preparation method and application of antibody</title><source>esp@cenet</source><creator>ZHENG MINGJIN ; WANG JIELI ; ZHANG WEI</creator><creatorcontrib>ZHENG MINGJIN ; WANG JIELI ; ZHANG WEI</creatorcontrib><description>The invention discloses an antibody targeting CLDN18.2, and a preparation method and application of the antibody. The antibody comprises VL and/or VH, wherein the VH comprises the following CDR sequences: a VH CDR1 amino acid sequence as shown in SEQ ID NO: 6, a VH CDR2 amino acid sequence as shown in SEQ ID NO: 7, and/or a VH CDR3 amino acid sequence as shown in SEQ ID NO: 8; and the VL comprises the following CDR sequences: a VL CDR1 amino acid sequence as shown in SEQ ID NO: 17, a VL CDR2 amino acid sequence as shown in SEQ ID NO: 18, and/or a VL CDR3 amino acid sequence as shown in SEQ ID NO: 19. Compared with the prior art, the antibody provided by the invention has obvious advantages of high binding affinity, good ADCC, CDC and growth inhibition effects, high endocytosis activity and the like.
本发明公开了靶向CLDN18.2的抗体及其制备方法和应用。所述抗体包含VL和/或VH，所述VH包含以下CDR序列：如SEQ ID NO:6所示的VH CDR1氨基酸序列；如SEQ ID NO:7所示的VH CDR2氨基酸序列；和/或如SEQ ID NO:8所示的VH CDR3氨基酸序列；所述VL包含以下的CDR序列：如SEQ ID NO:17所示的VL CDR1氨基酸序列；如SEQ ID NO:18所示的VL CDR2氨基</description><language>chi ; eng</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2021</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210427&DB=EPODOC&CC=CN&NR=112707965A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210427&DB=EPODOC&CC=CN&NR=112707965A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>ZHENG MINGJIN</creatorcontrib><creatorcontrib>WANG JIELI</creatorcontrib><creatorcontrib>ZHANG WEI</creatorcontrib><title>Antibody targeting CLDN18.2, and preparation method and application of antibody</title><description>The invention discloses an antibody targeting CLDN18.2, and a preparation method and application of the antibody. The antibody comprises VL and/or VH, wherein the VH comprises the following CDR sequences: a VH CDR1 amino acid sequence as shown in SEQ ID NO: 6, a VH CDR2 amino acid sequence as shown in SEQ ID NO: 7, and/or a VH CDR3 amino acid sequence as shown in SEQ ID NO: 8; and the VL comprises the following CDR sequences: a VL CDR1 amino acid sequence as shown in SEQ ID NO: 17, a VL CDR2 amino acid sequence as shown in SEQ ID NO: 18, and/or a VL CDR3 amino acid sequence as shown in SEQ ID NO: 19. Compared with the prior art, the antibody provided by the invention has obvious advantages of high binding affinity, good ADCC, CDC and growth inhibition effects, high endocytosis activity and the like.
本发明公开了靶向CLDN18.2的抗体及其制备方法和应用。所述抗体包含VL和/或VH，所述VH包含以下CDR序列：如SEQ ID NO:6所示的VH CDR1氨基酸序列；如SEQ ID NO:7所示的VH CDR2氨基酸序列；和/或如SEQ ID NO:8所示的VH CDR3氨基酸序列；所述VL包含以下的CDR序列：如SEQ ID NO:17所示的VL CDR1氨基酸序列；如SEQ ID NO:18所示的VL CDR2氨基</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2021</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZPB3zCvJTMpPqVQoSSxKTy3JzEtXcPZx8TO00DPSUUjMS1EoKEotSCxKLMnMz1PITS3JyE8BCycWFORkJkOE89OAQhBjeBhY0xJzilN5oTQ3g6Kba4izh25qQX58anFBYnJqXmpJvLOfoaGRuYG5pZmpozExagCpqjXG</recordid><startdate>20210427</startdate><enddate>20210427</enddate><creator>ZHENG MINGJIN</creator><creator>WANG JIELI</creator><creator>ZHANG WEI</creator><scope>EVB</scope></search><sort><creationdate>20210427</creationdate><title>Antibody targeting CLDN18.2, and preparation method and application of antibody</title><author>ZHENG MINGJIN ; WANG JIELI ; ZHANG WEI</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CN112707965A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>chi ; eng</language><creationdate>2021</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>ZHENG MINGJIN</creatorcontrib><creatorcontrib>WANG JIELI</creatorcontrib><creatorcontrib>ZHANG WEI</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>ZHENG MINGJIN</au><au>WANG JIELI</au><au>ZHANG WEI</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Antibody targeting CLDN18.2, and preparation method and application of antibody</title><date>2021-04-27</date><risdate>2021</risdate><abstract>The invention discloses an antibody targeting CLDN18.2, and a preparation method and application of the antibody. The antibody comprises VL and/or VH, wherein the VH comprises the following CDR sequences: a VH CDR1 amino acid sequence as shown in SEQ ID NO: 6, a VH CDR2 amino acid sequence as shown in SEQ ID NO: 7, and/or a VH CDR3 amino acid sequence as shown in SEQ ID NO: 8; and the VL comprises the following CDR sequences: a VL CDR1 amino acid sequence as shown in SEQ ID NO: 17, a VL CDR2 amino acid sequence as shown in SEQ ID NO: 18, and/or a VL CDR3 amino acid sequence as shown in SEQ ID NO: 19. Compared with the prior art, the antibody provided by the invention has obvious advantages of high binding affinity, good ADCC, CDC and growth inhibition effects, high endocytosis activity and the like.
本发明公开了靶向CLDN18.2的抗体及其制备方法和应用。所述抗体包含VL和/或VH，所述VH包含以下CDR序列：如SEQ ID NO:6所示的VH CDR1氨基酸序列；如SEQ ID NO:7所示的VH CDR2氨基酸序列；和/或如SEQ ID NO:8所示的VH CDR3氨基酸序列；所述VL包含以下的CDR序列：如SEQ ID NO:17所示的VL CDR1氨基酸序列；如SEQ ID NO:18所示的VL CDR2氨基</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | chi ; eng |
| recordid | cdi_epo_espacenet_CN112707965A |
| source | esp@cenet |
| subjects | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE |
| title | Antibody targeting CLDN18.2, and preparation method and application of antibody |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T07%3A40%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=ZHENG%20MINGJIN&rft.date=2021-04-27&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECN112707965A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |